AAAAAA

   
Results: 1-7 |
Results: 7
Cl-1033, a pan-erbB tyrosine kinase inhibitor
Authors: Slichenmyer, WJ Elliott, WL Fry, DW
Citation: Wj. Slichenmyer et al., Cl-1033, a pan-erbB tyrosine kinase inhibitor, SEMIN ONCOL, 28(5), 2001, pp. 80-85
Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of theepidermal growth factor receptor
Authors: Smaill, JB Showalter, HDH Zhou, HR Bridges, AJ McNamara, DJ Fry, DW Nelson, JM Sherwood, V Vincent, PW Roberts, BJ Elliott, WL Denny, WA
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of theepidermal growth factor receptor, J MED CHEM, 44(3), 2001, pp. 429-440
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity
Authors: Schroeder, MC Hamby, JM Connolly, CJC Grohar, PJ Winters, RT Barvian, MR Moore, CW Boushelle, SL Crean, SM Kraker, AJ Driscoll, DL Vincent, PW Elliott, WL Lu, GH Batley, BL Dahring, TK Major, TC Panek, RL Doherty, AM Showalter, HDH
Citation: Mc. Schroeder et al., Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity, J MED CHEM, 44(12), 2001, pp. 1915-1926
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
Authors: Vincent, PW Bridges, AJ Dykes, DJ Fry, DW Leopold, WR Patmore, SJ Roberts, BJ Rose, S Sherwood, V Zhou, HR Elliott, WL
Citation: Pw. Vincent et al., Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts, CANC CHEMOT, 45(3), 2000, pp. 231-238
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
Authors: Smaill, JB Rewcastle, GW Loo, JA Greis, KD Chan, OH Reyner, EL Lipka, E Showalter, HDH Vincent, PW Elliott, WL Denny, WA
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions, J MED CHEM, 43(7), 2000, pp. 1380-1397
3-(3,5-dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase
Authors: Thompson, AM Connolly, CJC Hamby, JM Boushelle, S Hartl, BG Amar, AM Kraker, AJ Driscoll, DL Steinkampf, RW Patmore, SJ Vincent, PW Roberts, BJ Elliott, WL Klohs, W Leopold, WR Showalter, HDH Denny, WA
Citation: Am. Thompson et al., 3-(3,5-dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase, J MED CHEM, 43(22), 2000, pp. 4200-4211
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions(vol 43, pg 1380, 2000)
Authors: Smaill, JB Rewcastle, GW Bridges, AJ Zhou, HR Showalter, HDH Fry, DW Nelson, JM Sherwood, V Elliott, WL Vincent, PW DeJohn, DE Loo, JA Greis, KD Chan, OH Reyner, EL Lipka, E Denny, WA
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions(vol 43, pg 1380, 2000), J MED CHEM, 43(16), 2000, pp. 3199-3199
Risultati: 1-7 |